WOCKPHARMA

Financial Performance & Strategic Shifts

Wockhardt Limited has reached several major clinical and financial milestones recently, positioning itself as a key player in the global fight against antimicrobial resistance. The company has shifted its focus away from US generics toward high-value novel antibiotics and biotechnology. Regulatory & Clinical Breakthroughs Zaynich (WCK 5222) US FDA Milestone: In December 2025, Wockhardt achieved a historic first for the Indian pharmaceutical industry when the US FDA accepted its New Drug Application (NDA) for Zaynich. This is the first time a New Chemical Entity (NCE) fully developed by an Indian company has reached this stage. The drug has been granted Fast Track designation to address life-threatening, multi-drug resistant infections. European Expansion: On January 5, 2026, the company filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for Zaynich. The EMA granted the drug Accelerated Assessment, which could lead to approval across 30 European countries by mid-2026. Foviscu (WCK 4282) Success: In February 2026, Wockhardt announced that its novel antibiotic Foviscu successfully met its primary endpoints in a pivotal Phase 3 trial. It demonstrated a 93.23% clinical cure rate, showing therapeutic equivalence to the gold-standard treatment, Meropenem. Nafithromycin (Miqnaf) Launch: In May 2025, Wockhardt launched Miqnaf in India, the country’s first indigenous respiratory antibiotic in over 30 years. It is designed to treat community-acquired bacterial pneumonia with a short three-day oral course. Financial Performance & Strategic Shifts Q3 FY2025-26 Results: Wockhardt reported a significant turnaround in its third-quarter results ending December 31, 2025. Consolidated revenue rose 23% year-over-year to ₹888 crore. Net profit surged to ₹61 crore, a massive jump from ₹20 crore in the same period the previous year.